Surmodics (SRDX) Stock Price, News & Analysis

Company Overview

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Key Stats

• Today's Range: $33.97 to $34.51
• 50-Day Range: $28.81 to $38.00
• 52-Week Range: $26.00 to $40.38
• Volume: 100,645 shs
• Average Volume: 320,956 shs
• Market Capitalization: $486.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Hold

Surmodics Stock Analysis - MarketRank™

Surmodics scored higher than 88% of companies evaluated by MarketBeat, and ranked 132nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Surmodics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Surmodics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 300.00%

Earnings Growth

Earnings for Surmodics are expected to grow by 300.00% in the coming year, from $0.20 to $0.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Surmodics is -27.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surmodics is -27.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Surmodics has a P/B Ratio of 4.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.81% of the float of Surmodics has been sold short.

Short Interest Ratio / Days to Cover

Surmodics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Surmodics has recently increased by 16.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surmodics does not currently pay a dividend.

Dividend Growth

Surmodics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.52

Percentage of Shares Shorted

2.81% of the float of Surmodics has been sold short.

Short Interest Ratio / Days to Cover

Surmodics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Surmodics has recently increased by 16.18%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.73

News Sentiment

Surmodics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Surmodics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for SRDX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surmodics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.90% of the stock of Surmodics is held by insiders.

Percentage Held by Institutions

96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRDX Stock Analysis - Frequently Asked Questions

How have SRDX shares performed this year?

Surmodics' stock was trading at $39.60 at the beginning of the year. Since then, SRDX stock has decreased by 14.0% and is now trading at $34.04.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings results on Friday, August, 8th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.27. The business had revenue of $29.57 million for the quarter, compared to analysts' expectations of $28.04 million. Surmodics had a negative net margin of 14.59% and a negative trailing twelve-month return on equity of 2.99%.

Who are Surmodics' major shareholders?

Top institutional investors of Surmodics include Alliancebernstein L.P. (5.95%), Gabelli Funds LLC (2.90%), Hudson Bay Capital Management LP (2.80%) and Hudson Bay Capital Management LP (2.80%). Insiders that own company stock include Timothy J Arens, David Dantzker, Ronald B Sr Kalich Sr and Jose H Bedoya.
View institutional ownership trends.

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 9/01/2025
• Fiscal Year End: 9/30/2025
• Next Earnings (Estimated): 11/05/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:SRDX
• CIK: 924717
• Web: www.surmodics.com
• Phone: (952) 500-7000
• Fax: 952-500-7001
• Employees: 450
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Surmodics: $43.00
• High Price Target: $43.00
• Low Price Target: $43.00
• Potential Upside/Downside: +26.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 170.20
• P/E Growth: N/A
• Net Income: -$11.54 million
• Net Margins: -14.59%
• Pretax Margin: -12.16%
• Return on Equity: -2.99%
• Return on Assets: -1.99%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 3.91
• Quick Ratio: 3.10

Sales & Book Value

• Annual Sales: $120.80 million
• Price / Sales: 4.03
• Cash Flow: $0.31 per share
• Price / Cash Flow: 110.03
• Book Value: $8.33 per share
• Price / Book: 4.09

Miscellaneous

• Outstanding Shares: 14,298,000
• Free Float: 13,025,000
• Market Cap: $486.70 million
• Optionable: Optionable
• Beta: 1.37